The potential of FLI1 as a therapeutic target in human autoimmune diseases such as systemic sclerosis and systemic lupus erythematosus has been proposed, and the loss of FLI1 in CD8+ T cells enhances immunity to tumors has also been reported [41, 45]. This evidence concerns the gene CD8A and systemic lupus erythematosus.